| Name | Title | Contact Details |
|---|
Celyad is a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies. With product candidates in oncology and cardiology, Celyad seeks to address diseases with high unmet medical needs such as heart failure and cancer. Founded in 2007, Celyad leverages unique know-how in taking cell based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products. Celyad builds it business model on partnering with prominent research institutions such as the Mayo Clinic and Dartmouth College, and develops those programs from bench to commercial applications.
Peer Direct is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Supply Chain Logistics is a Utica, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kala Pharmaceuticals, Inc. (Kala) is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Co-founded in 2009 by recognized experts in the field of nanomedicine Professors Justin Hanes and Robert Langer, pharmaceutical industry veteran Dr. Colin Gardner, and leading life sciences investors, Kala utilizes a multi-disciplinary scientific approach and internal expertise in all stages of pharmaceutical development with the goal of translating its MPP technology into products that seek to address unmet therapeutic needs. Kala`s lead program, a shelf-stable MPP nanosuspension of an ophthalmic corticosteroid, is in clinical trials for the treatment of post-surgical ocular inflammation, dry eye disease, and meibomian gland disease. Kala is also advancing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD). Beyond ophthalmology, Kala`s MPP technology has potential applications in women`s reproductive health, respiratory and gastrointestinal diseases, and other indications. The name Kala was inspired by the famous Kalalau trail, a hiking trail on the island of Kauai, Hawaii. This trail is not only notable for its strenuous path and terrain that is difficult to traverse but also known for its unsurpassed beauty.
Avecia Biotechnology is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.